![Jesse Cotari](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
Jesse Cotari is associated with ImmuneBridge, Inc. as the Chief Scientific Officer since 2018.
Dr. Cotari is the founder of ImmuneBridge, Inc. which was founded in 2018.
Postes actifs de Jesse Cotari
Sociétés | Poste | Début |
---|---|---|
ImmuneBridge, Inc.
![]() ImmuneBridge, Inc. BiotechnologyHealth Technology ImmuneBridge, Inc. is a biotech company that is developing the next generation of allogeneic cellular medicines to make curative cancer therapies accessible to everyone. The company is based in San Francisco, CA and was founded in 2018 by Jesse Cotari and Peretz Partensky. The company is starting with NK cell-based immunotherapies. The company's proprietary expansion technology amplifies cord blood-derived immune stem cells while maintaining full immune multipotency to create a consistent and abundant cellular source for immunotherapies. ImmuneBridge's scientific approach harnesses this expansion technology along with the unique benefits of umbilical cord blood to enable robust screening and selection for the most potent cancer-fighting cells. Peretz Partensky has been the CEO since 2018. | Fondateur | 01/01/2018 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 1 |
---|---|
ImmuneBridge, Inc.
![]() ImmuneBridge, Inc. BiotechnologyHealth Technology ImmuneBridge, Inc. is a biotech company that is developing the next generation of allogeneic cellular medicines to make curative cancer therapies accessible to everyone. The company is based in San Francisco, CA and was founded in 2018 by Jesse Cotari and Peretz Partensky. The company is starting with NK cell-based immunotherapies. The company's proprietary expansion technology amplifies cord blood-derived immune stem cells while maintaining full immune multipotency to create a consistent and abundant cellular source for immunotherapies. ImmuneBridge's scientific approach harnesses this expansion technology along with the unique benefits of umbilical cord blood to enable robust screening and selection for the most potent cancer-fighting cells. Peretz Partensky has been the CEO since 2018. | Health Technology |